Simple Summary: To date, one of the reference therapies for the treatment of mutated BRAF metastatic melanoma is based on the combination of BRAF and MEK inhibitors. Although many trials...
We aim to review the current knowledge and potential fields of research regarding the use of BRAF inhibitors in metastatic colorectal tumors. Metastatic colorectal cancer (mCRC) with...
BRAF is a human gene that encodes a protein called B-Raf. The gene... Certain other inherited BRAF mutations cause birth defects. Drugs that treat cancers driven by BRAF mutations have been...
Cancers, Vol 15, Iss 1, p 141 (2022) ; 자료유형 : article, Content Provider : Directory of Open Access Journals, 초록 : Purpose: This meta-analysis summarizes the incidence of treatment-related adverse events (AE) of BRAFi and MEKi. Methods: A systematic search of Medline/PubMed was conducted to identify suitable articles published in English up to 31 December 2021. The primary outcomes were profiles for all-grade and grade 3 or higher treatment-related AEs, and the analysis of single side effects belonging to both categories. Results: Th ...
Accept all cookies Manage preferences Published: 21 October 2014 Skin cancer BRAF and MEK inhibitors—good news comes in twos! David Killock Nature Reviews Clinical Oncology 11, 683 (2014)...
a BRAF inhibitor and radiation therapy has recently been reported. Material and Methods: We... B-raf / *antagonists & inhibitors Radiation-Sensitizing Agents / *adverse effects Radiation...
the potential of alternative combination therapies to either delay the onset of resistance to MAPK inhibitors or directly target specific mechanisms of resistance to BRAF/MEK inhibitors.
The BRAF gene provides instructions to a protein responsible for managing important cell functions related to growth. ; If there is a mutation in the gene, it stops working correctly and signals cells to divide uncontrollably, which leads to a tumor. ; Doctors can collect and analyze a sample of the tumor or use blood tests to detect the BRAF mutation.
Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial...
GeneCards Symbol: BRAF · 2 ; B-Raf Proto-Oncogene, Serine/Threonine Kinase · 235 ; BRAF1 · 2345 ; BRAF-1 · 235 ; V-Raf Murine Sarcoma Viral Oncogene Homolog B1 · 34 ; V-Raf Murine Sarcoma Viral Oncogene Homolog B · 23 ; Serine/Threonine-Protein Kinase B-Raf · 34 ; Proto-Oncogene B-Raf · 34 ; RAFB1 · 34